Compare BTBT & CTKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTBT | CTKB |
|---|---|---|
| Founded | 2015 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.7M | 652.1M |
| IPO Year | 2017 | 2021 |
| Metric | BTBT | CTKB |
|---|---|---|
| Price | $1.62 | $4.01 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 5 |
| Target Price | ★ $7.00 | $5.70 |
| AVG Volume (30 Days) | ★ 19.4M | 687.9K |
| Earning Date | 01-01-0001 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 218.75 | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | $108,050,720.00 | ★ $193,015,000.00 |
| Revenue This Year | $7.15 | $5.02 |
| Revenue Next Year | $90.95 | $7.89 |
| P/E Ratio | $3.52 | ★ N/A |
| Revenue Growth | ★ 140.56 | 17.67 |
| 52 Week Low | $1.49 | $2.37 |
| 52 Week High | $4.55 | $6.18 |
| Indicator | BTBT | CTKB |
|---|---|---|
| Relative Strength Index (RSI) | 42.04 | 30.90 |
| Support Level | $1.53 | $3.81 |
| Resistance Level | $2.43 | $4.26 |
| Average True Range (ATR) | 0.11 | 0.21 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 10.94 | 9.23 |
Bit Digital Inc is engaged in the Bitcoin mining business, Ethereum staking activities and specialized cloud-infrastructure services for artificial intelligence applications through its wholly owned subsidiaries. Its mining platform operates with the primary intent of accumulating bitcoin which may sell for fiat currency from time to time depending on market conditions. The Company has four reportable segments: digital asset mining, cloud services, colocation services, and ETH Staking. It generates majority of its revenue from digital asset mining.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.